RxDoctor Payments Data

Kevin Sisk, DO

Family Medicine · Blair, NENPI 1629330535

Payments from drug & device makers

$1,151in general payments, 2019–2025

Across 66 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$220
  • Lilly USA, LLC$181
  • Pfizer$160
  • AbbVie$140
  • Amgen$114
  • Novo Nordisk$59
  • plus $277 from 12 others

What the payments were for

  • Food & beverage$1,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,151 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$16,009
Medicare patients
74
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$85,597
MounjaroTirzepatide69$75,376
OzempicSemaglutide43$45,584
TrulicityDulaglutide34$37,616
JardianceEmpagliflozin22$30,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$30,006
MyrbetriqMirabegron61$26,854
JanuviaSitagliptin Phosphate51$24,949
XareltoRivaroxaban17$14,762
FarxigaDapagliflozin Propanediol17$14,600
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$9,277
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$8,772
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$8,277
Insulin Lispro Kwikpen U-100Insulin Lispro17$6,902
Atorvastatin Calcium525$6,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$181$115,669139 claims
PfizerEliquis$160$85,59788 claims
Novo NordiskOzempic$59$45,58443 claims
Astellas Pharma US IncMyrbetriq$57$26,85461 claims
MerckJanuvia$18$24,94951 claims
AstraZenecaFarxiga$220$14,60017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Blair

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →